Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
This is an extension study for studies MK-7962-007 (NCT04945460) and MK-7962-041 (NCT number pending).
Following protocol amendment 3, all participants in the Sotatercept 0.7 mg/kg arm will switch to the Sotatercept 0.3 mg/kg arm, and new participants will only enroll in the Sotatercept 0.3 mg/kg arm.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\- Completed sotatercept parent study (MK-7962-007\[CADENCE\] \[Visit 9 and EOT visit\] or MK-7962-041 \[P041\] \[EOT Visit\]) without discontinuing study intervention and is able to safely enroll into MK-7962-023 (HARMONIZE)
You may not be if
Has a diagnosis of pulmonary hypertension (PH) in world health organization (WHO) Group 1, WHO Group 3, WHO Group 4, or WHO Group 5
Has had a study intervention interruption and has an ongoing SAE that occurred during parent study and is suspected to be related to study intervention
Is pregnant or breastfeeding
Has chronic liver disease with severe hepatic impairment and/or cirrhosis (eg, hepatic encephalopathy)
Anticipation of more than 1 valve replacement or repair (mechanical or biomechanical) and/or have undergone more than 1 valve replacement or repair
Has severe tricuspid regurgitation due to primary valvular disease (eg, from endocarditis, carcinoid, or mechanical destruction)
Anticipated or undergone heart transplant or ventricular assist device implantation
